UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Randomized Controlled Trial of Danoprevir Plus Peginterferon Alfa-2a and Ribavirin in Treatment-Naïve Patients With Hepatitis C Virus Genotype 1 Infection

Gastroenterology (New York, N.Y. 1943), 2013-10, Vol.145 (4), p.790-800.e3

2013

Volltextzugriff (PDF)

Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents

Gastroenterology (New York, N.Y. 1943), 2018-08, Vol.155 (2), p.411-421.e4

2018

Volltextzugriff (PDF)

Risk of Hepatocellular Cancer in HCV Patients Treated with Direct Acting Antiviral Agents

Gastroenterology (New York, N.Y. 1943), 2017-10, Vol.153 (4), p.996-1005.e1

2017

Volltextzugriff (PDF)

What Are the Benefits of a Sustained Virologic Response to Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection?

Gastroenterology (New York, N.Y. 1943), 2019-01, Vol.156 (2), p.446-460.e2

2019

Volltextzugriff (PDF)

Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges

Gastroenterology (New York, N.Y. 1943), 2019-01, Vol.156 (2), p.431-445

2019

Volltextzugriff (PDF)

Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications

Gastroenterology (New York, N.Y. 1943), 2017-01, Vol.152 (1), p.142-156.e2

2017

Volltextzugriff (PDF)

Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis

Gastroenterology (New York, N.Y. 1943), 2017-11, Vol.153 (5), p.1273-1283.e1

2017

Volltextzugriff (PDF)

Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study

Gastroenterology (New York, N.Y. 1943), 2019-05, Vol.156 (6), p.1683-1692.e1

2019

Volltextzugriff (PDF)

Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease

Gastroenterology (New York, N.Y. 1943), 2016-06, Vol.150 (7), p.1590-1598

2016

Volltextzugriff (PDF)

Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir

Gastroenterology (New York, N.Y. 1943), 2016-09, Vol.151 (3), p.501-512.e1

2016

Volltextzugriff (PDF)

Fibrosis Regression After Eradication of Hepatitis C Virus: From Bench to Bedside

Gastroenterology (New York, N.Y. 1943), 2021-04, Vol.160 (5), p.1502-1520.e1

2021

Volltextzugriff (PDF)

Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System

Gastroenterology (New York, N.Y. 1943), 2016-09, Vol.151 (3), p.457-471.e5

2016

Volltextzugriff (PDF)

Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

Gastroenterology (New York, N.Y. 1943), 2017-07, Vol.153 (1), p.113-122

2017

Volltextzugriff (PDF)

AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review

Gastroenterology (New York, N.Y. 1943), 2019-06, Vol.156 (8), p.2149-2157

2019

Volltextzugriff (PDF)

Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection

Gastroenterology (New York, N.Y. 1943), 2017-01, Vol.152 (1), p.164-175.e4

2017

Volltextzugriff (PDF)

Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response

Gastroenterology (New York, N.Y. 1943), 2016-12, Vol.151 (6), p.1131-1140.e5

2016

Volltextzugriff (PDF)

Efficacy and Safety of Sofosbuvir plus Daclatasvir for Treatment of HCV-associated Cryoglobulinemia Vasculitis

Gastroenterology (New York, N.Y. 1943), 2017-07, Vol.153 (1), p.49-52.e5

2017

Volltextzugriff (PDF)

Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension

Gastroenterology (New York, N.Y. 1943), 2016-07, Vol.151 (1), p.130-139.e2

2016

Volltextzugriff (PDF)

Long-Term Outcomes of Patients With HCV-Associated Cryoglobulinemic Vasculitis After Virologic Cure

Gastroenterology (New York, N.Y. 1943), 2018-08, Vol.155 (2), p.311-315.e6

2018

Volltextzugriff (PDF)

Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy

Gastroenterology (New York, N.Y. 1943), 2019-03, Vol.156 (4), p.997-1009.e5

2019

Volltextzugriff (PDF)

Intra-Hepatic Depletion of Mucosal-Associated Invariant T Cells in Hepatitis C Virus-Induced Liver Inflammation

Gastroenterology (New York, N.Y. 1943), 2017-11, Vol.153 (5), p.1392-1403.e2

2017

Volltextzugriff (PDF)

High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis

Gastroenterology (New York, N.Y. 1943), 2016-10, Vol.151 (4), p.651-659.e1

2016

Volltextzugriff (PDF)

Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection

Gastroenterology (New York, N.Y. 1943), 2017-05, Vol.152 (6), p.1383-1394

2017

Volltextzugriff (PDF)

Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis

Gastroenterology (New York, N.Y. 1943), 2017-05, Vol.152 (6), p.1372-1382.e2

2017

Volltextzugriff (PDF)

1 – 25 von 43

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieGastroenterology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(43)

Publikationsform

Artikel
(43)

Sprache

Englisch
(43)

Erscheinungsjahr

n.n

Thema

Gastroenterology & Hepatology
(43)
Humans
(43)
Life Sciences & Biomedicine
(43)
Science & Technology
(43)
Sustained Virologic Response
(43)
Male
(33)
Female
(31)
Antiviral Agents - Therapeutic Use
(30)
Middle Aged
(30)
Gastroenterology And Hepatology
(25)
Hepatitis C, Chronic - Drug Therapy
(24)
Drug Therapy, Combination
(22)
Aged
(20)
Hepacivirus - Genetics
(19)
Hepatitis C - Drug Therapy
(18)
Genotype
(17)
Hepacivirus - Drug Effects
(15)
Adult
(14)
Antiviral Agents - Administration & Dosage
(14)
Liver Cirrhosis - Virology
(13)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(43)
Ingenta
(43)
Elsevier ScienceDirect Journals Complete
(43)
Single Journals
(43)

Menü

Weitere Dienste

Einstellungen

Randomized Controlled Trial of Danoprevir Plus Peginterferon Alfa-2a and Ribavirin in Treatment-Naïve Patients With Hepatitis C Virus Genotype 1 Infection

Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents

Risk of Hepatocellular Cancer in HCV Patients Treated with Direct Acting Antiviral Agents

What Are the Benefits of a Sustained Virologic Response to Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection?

Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges

Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications

HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response

Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis

Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study

Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease

Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir

Fibrosis Regression After Eradication of Hepatitis C Virus: From Bench to Bedside

Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System

Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review

Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection

Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response

Efficacy and Safety of Sofosbuvir plus Daclatasvir for Treatment of HCV-associated Cryoglobulinemia Vasculitis

Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension

Long-Term Outcomes of Patients With HCV-Associated Cryoglobulinemic Vasculitis After Virologic Cure

Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy

Intra-Hepatic Depletion of Mucosal-Associated Invariant T Cells in Hepatitis C Virus-Induced Liver Inflammation

High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis

Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection

Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis

Aktive Filter

Suchergebnisse filtern